Fennec Pharmaceuticals (FENC) Share-based Compensation (QoQ) (2010 - 2025)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Fennec Pharmaceuticals | 281.48 Mn | 244.70 Mn | 7.67 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 13.65% |
| Sep 30, 2025 | 48.53% |
| Jun 30, 2025 | 87.22% |
| Mar 31, 2025 | -29.00% |
| Dec 31, 2024 | -38.28% |
| Sep 30, 2024 | 96.86% |
| Jun 30, 2024 | -22.33% |
| Mar 31, 2024 | 38.97% |
| Dec 31, 2023 | -0.92% |
| Sep 30, 2023 | -65.99% |
| Jun 30, 2023 | 133.52% |
| Mar 31, 2023 | 3,530.00% |
| Dec 31, 2022 | -11.76% |
| Sep 30, 2022 | -2.86% |
| Jun 30, 2022 | 2.94% |
| Mar 31, 2022 | -99.09% |
| Dec 31, 2021 | 307.85% |
| Sep 30, 2021 | -30.84% |
| Jun 30, 2021 | 125.89% |
| Mar 31, 2021 | 2,695.24% |
| Dec 31, 2020 | -98.30% |
| Sep 30, 2020 | 5,795.24% |
| Jun 30, 2020 | -94.63% |
| Mar 31, 2020 | 300.51% |
| Dec 31, 2019 | -1,028.57% |
| Sep 30, 2019 | -93.66% |
| Jun 30, 2019 | 49.77% |
| Mar 31, 2019 | -86.03% |
| Dec 31, 2018 | 3,339.13% |
| Sep 30, 2018 | -44.58% |
| Jun 30, 2018 | -52.30% |
| Mar 31, 2018 | -81.97% |
| Dec 31, 2017 | 6.39% |
| Sep 30, 2017 | 217.13% |
| Jun 30, 2017 | 410.71% |
| Mar 31, 2017 | 187.50% |
| Dec 31, 2016 | -328.57% |
| Sep 30, 2016 | 64.71% |
| Mar 31, 2015 | -95.08% |
| Dec 31, 2014 | 50.00% |
| Mar 31, 2014 | 468.57% |
| Dec 31, 2013 | -185.37% |
| Sep 30, 2013 | 41.38% |
| Sep 30, 2011 | 163.27% |
| Sep 30, 2010 | -81.21% |